In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
Bayer Zydus Pharma will continue to operate in core therapies with new products in the pipeline
The company's operating revenue for Q4 FY21 was Rs. 330.2 crore
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Jubilant successfully challenged Bracco's patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The Department of Pharmaceuticals launched the PLI scheme for promoting domestic manufacturing of bulk drugs, with a financial outlay of Rs. 6,940 crore across 53 APIs over 6 years
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Biocon Pharma will be responsible for drug development and manufacturing, while Libbs will leverage its deep expertise and reach in Brazil to import, distribute and market
Subscribe To Our Newsletter & Stay Updated
